Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 16/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14950501 | 0.90 | TLR2 (0.58) | TLR2LPAR1LPAR3 | |
| SCHEMBL14924383 | 0.89 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL15071438 | 0.89 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL18057125 | 0.89 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL18057124 | 0.89 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL14924385 | 0.89 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL11304197 | 0.89 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL10819300 | 0.89 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL25515284 | 0.89 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL24470621 | 0.87 | TLR2 (0.64) | TLR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200282060-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-09-10 | — | — | US | disclosed |
| US-20170151333-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-06-01 | — | — | US | disclosed |
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130116307-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS INC. (CA) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116307-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | LDLR, CETP, ABHD16A | TLR2 1612/4885LPAR1 26/4885LPAR3 12/4885 |
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | TLR2 1362/4885LPAR1 68/4885LPAR3 34/4885 |
| US-20200282060-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | TLR2 1362/4885LPAR1 68/4885LPAR3 34/4885 |
| US-20170151333-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | TLR2 1362/4885LPAR1 68/4885LPAR3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.